Opportunities and Approaches for Supplying Molybdenum-99 and Associated Medical Isotopes to Global Markets Proceedings of a Symposium (2018) / Chapter Skim
Currently Skimming:
Overview
Overview
Pages 1-4
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 1... ...
A representative of the Russian State Atomic Energy Corporation, Rosatom, noted that Russia realizes that selling non-HEU-sourced molybdenum-99 is a recognized requirement for producers aspiring to capture a share of the global market. The representative added that Rosatom, for economic reasons, has chosen not to prioritize conversion of production from using HEU to LEU targets in existing reactors but instead to invest in alternative non-HEU production methods with a goal of capturing up to a 20 percent share of the global market in the future.
|
From page 2... ...
These actions include increasing production capacity and outage reserve capacity, monitoring and reviewing the supply chain to identify periods of potential risk, investing in the durability of the supply, coordinating reactor schedules, enhancing communications among supply chain participants, and developing backup agreements between producers and reactor operators. Many symposium participants noted that the supply market is more reliable today as a result of these actions.
|
From page 3... ...
Several symposium participants offered comments on their company's or organization's views on adoption of the full cost recovery principle. These comments highlight the range of existing and anticipated differences in estimating molybdenum-99 production costs and interpreting full cost recovery.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.